40th Annual Winter Urologic Forum
January 16 – 19, 2016
Vail Marriott Mountain Resort  |  Vail, Colorado

PROGRAM PLANNING COMMITTEE
Mitchell C. Benson, MD (Chair)
Roger R. Dmochowski, MD, MMHC, FACS
Christopher P. Evans, MD, FACS
James M. McKiernan, MD

Sponsored by:
University of California, Davis; Columbia University; and Vanderbilt University
# Table of Contents

**40th Annual Winter Urologic Forum**  
January 16 - 19, 2016  
Vail Mountain Resort  
Vail, Colorado

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Meeting Information</td>
<td>Page 3</td>
</tr>
<tr>
<td>Faculty</td>
<td>Page 4</td>
</tr>
<tr>
<td>Faculty Disclosures</td>
<td>Page 5</td>
</tr>
<tr>
<td>Educational Needs</td>
<td>Page 8</td>
</tr>
<tr>
<td>Educational Objectives</td>
<td>Page 9</td>
</tr>
<tr>
<td>Accreditation</td>
<td>Page 10</td>
</tr>
<tr>
<td>Promotional Partners and Contributors</td>
<td>Page 11</td>
</tr>
<tr>
<td>Exhibitors</td>
<td>Page 12</td>
</tr>
<tr>
<td>Industry Satellite Symposium Events</td>
<td>Page 13</td>
</tr>
<tr>
<td>Scientific Sessions</td>
<td>Page 14</td>
</tr>
<tr>
<td>Faculty Biographies</td>
<td>Page 18</td>
</tr>
</tbody>
</table>

---

**Winter Urologic Forum**
REGISTRATION/INFORMATION DESK HOURS
Friday, January 15, 2016               5:00 p.m. – 7:00 p.m.
Location: Grand Ballroom Registration Desk, Conference Level

Saturday, January 16, 2016               6:00 a.m. – 9:00 a.m
Location: Grand Ballroom Registration Desk, Conference Level

Sunday, January 17, 2016               6:30 a.m. – 9:00 a.m
Location: Grand Ballroom Registration Desk, Conference Level

Monday, January 18, 2016               6:30 a.m. – 9:00 a.m
Location: Grand Ballroom Registration Desk, Conference Level

Tuesday, January 19, 2016               6:30 a.m. – 9:00 a.m.
Location: Colorado Ballroom Foyer, 2nd Level

EXHIBIT HALL HOURS
Saturday, January 16, 2016               7:00 a.m. – 9:30 a.m.
Location: Grand Ballroom Salon F, Conference Level

Sunday, January 17, 2016               7:00 a.m. – 9:30 a.m.
Location: Grand Ballroom Salon F, Conference Level

Monday, January 18, 2016               7:00 a.m. – 10:30 a.m.
Location: Grand Ballroom Salon F, Conference Level

EVENING FUNCTION
Welcome Reception
Date: Saturday, January 16, 2016
Time: 6:45 p.m. – 7:45 p.m.
Location: Grand Ballroom Salon F, Conference Level
Attire: Business casual
Attendees can visit with exhibitors while connecting with fellow attendees and enjoying a variety of appetizers. One ticket is included in your registration fee.
Winter Urologic Forum 2016 Faculty

Daniel A. Barocas, MD, MPH, FACS
Vanderbilt University Medical Center
Nashville, TN

Mitchell C. Benson, MD
Columbia University
New York, NY

Kimberly L. Cooper, MD
Columbia University
New York, NY

Marc A. Dall’Era, MD
University of California, Davis
Sacramento, CA

Roger R. Dmochowski, MD, MMHC, FACS
Vanderbilt University Medical Center
Nashville, TN

Christopher P. Evans, MD, FACS
University of California, Davis
Sacramento, CA

Eric A. Kurzrock, MD, FAAP
University of California, Davis
Sacramento, CA

Roger K. Low, MD
University of California, Davis
Sacramento, CA

James M. McKiernan, MD
Columbia University
New York, NY

Douglas F. Milam, MD
Vanderbilt University Medical Center
Nashville, TN

Alan M. Nieder, MD
Mount Sinai Medical Center
Miami Beach, FL

Jennifer Rothschild, MD, MPH
University of California, Davis
Sacramento, CA

Ben B. Rubinowitz, JD
Gair, Gair, Conason, Steigman, Mackauf, Bloom & Rubinowitz
New York, NY

Matthew Rutman, MD
Columbia University
New York, NY

Ojas Shah, MD
Columbia University
New York, NY

Program Committee
Mitchell C. Benson, MD (Chair)
Roger R. Dmochowski, MD, MMHC, FACS
Christopher P. Evans, MD, FACS
James McKiernan, MD
FACULTY DISCLOSURE REPORT
40th Annual Winter Urologic Forum
January 15 - 19, 2016
Vail, CO

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.” It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.

ACS is also required, through our joint providership partners, to manage any reported conflict and eliminate the potential for bias during the activity. All program committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure and to allow the audience to form its own judgments regarding the presentation.

<table>
<thead>
<tr>
<th>PLANNING COMMITTEE / CME ORGANIZERS</th>
<th>Company</th>
<th>Role</th>
<th>Received</th>
</tr>
</thead>
<tbody>
<tr>
<td>BENSON, MD, Mitchell CME Organizer, Speaker, Moderator, Panelist</td>
<td>Astellas Pharmaceuticals, Janssen Pharmaceuticals</td>
<td>Speakers Bureau</td>
<td>Honorarium</td>
</tr>
<tr>
<td>DMOCHOWSKI, MD, MMHC, FACS, Roger CME Organizer, Speaker, Moderator, Panelist</td>
<td>Allergan</td>
<td>Consultant</td>
<td>Honorarium</td>
</tr>
<tr>
<td>Medtronic</td>
<td>Consultant</td>
<td>Honorarium</td>
<td></td>
</tr>
<tr>
<td>EVANS, MD, FACS, Christopher CME Organizer, Speaker, Moderator, Panelist</td>
<td>DOD, NIH, Medivation, BGI, SU2C - AACR, Sanofi, Janssen</td>
<td>Research Support</td>
<td>Grants/Research Support</td>
</tr>
<tr>
<td>Medivation, Astellas, Janssen, Sanofi</td>
<td>Consultant</td>
<td>Consultant</td>
<td></td>
</tr>
<tr>
<td>Oncogenix</td>
<td>Stock Shareholder</td>
<td>Stock Shareholder (directly purchased)</td>
<td></td>
</tr>
<tr>
<td>Janssen, Medivation, Bayer, Astellas, Sanofi</td>
<td>Speaker</td>
<td>Honorarium</td>
<td></td>
</tr>
<tr>
<td>MCKIERNAN, MD, James CME Organizer, Speaker, Moderator, Panelist</td>
<td>Nothing to disclose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPEAKERS / MODERATORS / PANELISTS / DISCUSSANTS / CO-AUTHORS</td>
<td>Company</td>
<td>Role</td>
<td>Received</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>-------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>BAROCAS, MD, MPH, FACS, Daniel</td>
<td></td>
<td>Nothing to disclose</td>
<td></td>
</tr>
<tr>
<td>BENSON, MD, Mitchell, CME Organizer, Speaker, Moderator, Panelist</td>
<td>Astellas Pharmaceuticals, Janssen Pharmaceuticals</td>
<td>Speakers Bureau</td>
<td>Honorarium</td>
</tr>
<tr>
<td>COOPER, MD, Kimberly, Speaker, Panelist</td>
<td></td>
<td>Nothing to disclose</td>
<td></td>
</tr>
<tr>
<td>DALL'ERA, MD, Marc, Speaker, Moderator, Panelist</td>
<td>Genomic Health, Speaker/ Consultant</td>
<td>Honorarium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bayer, Consultant</td>
<td>Honorarium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GenomeDx, Study Investigator</td>
<td>Grants/Research Support</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MDxHealth, Speaker/Consultant</td>
<td>Consultant</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janssen, Consultant</td>
<td>Consultant</td>
<td></td>
</tr>
<tr>
<td>DMOCHOWSKI, MD, MMHC, FACS, Roger, CME Organizer, Speaker, Moderator, Panelist</td>
<td>Allergan, Consultant</td>
<td>Honorarium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medtronic, Consultant</td>
<td>Honorarium</td>
<td></td>
</tr>
<tr>
<td>EVANS, MD, FACS, Christopher, CME Organizer, Speaker, Moderator, Panelist</td>
<td>DOD, NIH, Medivation, BGI, SU2C - AACR, Sanofi, Janssen</td>
<td>Research Support</td>
<td>Grants/Research Support</td>
</tr>
<tr>
<td></td>
<td>Medivation, Astellas, Janssen, Sanofi</td>
<td>Consultant</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oncogenix, Stock Shareholder</td>
<td>Stock Shareholder (directly purchased)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janssen, Medivation, Bayer, Astellas, Sanofi</td>
<td>Speaker</td>
<td>Honorarium</td>
</tr>
<tr>
<td>KURZROCK, MD, FAAP, Eric, Speaker</td>
<td>Allergan, consult on safety of Botox study</td>
<td>Consultant</td>
<td></td>
</tr>
<tr>
<td>LOW, MD, Roger, Speaker, Moderator</td>
<td>Medispec, Consultant</td>
<td>Consultant</td>
<td></td>
</tr>
<tr>
<td>SPEAKERS / MODERATORS / PANELISTS / DISCUSSANTS / CO-AUTHORS</td>
<td>Company</td>
<td>Role</td>
<td>Received</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td>---------------------------</td>
<td>-------------------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>MCKIERNAN, MD, James CME Organizer, Speaker, Moderator, Panelist</td>
<td></td>
<td>Nothing to disclose</td>
<td></td>
</tr>
<tr>
<td>MILAM, MD, Douglas Speaker, Panelist</td>
<td>Boston Scientific</td>
<td>Consultant</td>
<td>Consultant</td>
</tr>
<tr>
<td>NIEDER, MD, Alan Panelist</td>
<td>ferring speaker</td>
<td>Honorarium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Personalized Dx</td>
<td>Consultant</td>
<td></td>
</tr>
<tr>
<td>ROTHSCILD, MD, MPH, Jennifer Speaker, Panelist</td>
<td>American Medical Systems</td>
<td>Educational Grant</td>
<td>Grants/Research Support</td>
</tr>
<tr>
<td>RUBINOWITZ, JD, Ben Speaker, Panelist</td>
<td></td>
<td>Nothing to disclose</td>
<td></td>
</tr>
<tr>
<td>RUTMAN, MD, Matthew Panelist</td>
<td>Boston Scientific</td>
<td>Advisor</td>
<td>Consultant</td>
</tr>
<tr>
<td>SHAH, MD, Ojas Speaker</td>
<td>Boston Scientific</td>
<td>Consultant, lecturer, new product innovation</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>NJ Kidney Stone Center</td>
<td>Share owner - physician</td>
<td>Stock Shareholder (directly purchased)</td>
</tr>
</tbody>
</table>
Educational Needs

This meeting will identify for urologists new management strategies for prostate, and bladder cancer, lower urinary tract symptoms, incontinence, endourology, stone disease, pediatric urology and medical malpractice. Urologists attending this meeting will learn new ways to improve overall patient care.

Lower urinary tract symptoms and erectile dysfunction are linked in part by anatomy and physiology. As such, therapeutic approaches can combine and treat both these entities. The audience will learn the combined approaches to dual treatment. The use of penile prosthesis is common in the urologic patient population and the course will address the need to understand both the treatment options and potential complications. Some complications of prosthetic surgery lead to malpractice and a panel discussion will address how to minimize that risk.

The work-up and surgical treatment for male incontinence due to intrinsic sphincter dysfunction is important as prevalence and severity data suggests patients are being under-diagnosed and under-treated. In particular, urologists should be aware of the appropriate work-up to separate bladder from sphincter disorders and the best treatment options.

Urinary tract infections and painful urologic symptoms are common complaints to the urologist, but can be difficult to differentiate and treat. The appropriate evaluation and management for these overlapping conditions is important to ensure the best possible patient care. Legal issues surrounding the treatment of LUTS, specifically in the face of unprecedented legal concerns with synthetic pelvic mesh is important to the urologist practice.

Imaging for urinary stones has evolved and the consequences of too frequent radiation exposure are now evident. Imaging approaches will be addressed. Medical management of urinary stone disease is a large part of a urologic practice and the updated approaches will be reviewed. Upper tract ureteroscopy has become a cornerstone therapy for stone disease and select upper tract TCCA cases. ESWL remains popular, but selection of optimal cases and incorporating steps for optimizing results and reducing tissue damage can be a challenge. We will discuss surgical tips and tricks in surgical management of urolithiasis to bring the audience up to date on the latest approaches.

Many new options for prostate cancer detection exist and there is a gap in understanding how they work and which to choose. We will discuss new biomarkers and compare the use of genomic assays and MRI imaging of the prostate. The introduction of prostate cancer genomic testing may improve clinical risk-stratification, however the use of these novel costly tests must be balanced with concerns over prostate cancer resource utilization. This session will review the appropriate indications for the use of the currently available prostate cancer genomic tests. Additionally, there remains continued controversy over use of adjuvant versus salvage radiation therapy after prostatectomy. This session will review the choices and supporting data.

The incorporation of guideline based approaches to diagnosis and management of urothelial cancer is known to be poor in the US. The gap will be addressed by reviewing the key step to optimize outcomes for patients with bladder cancer. In addition, the use of BCG for non-invasive bladder cancer is often misunderstood. We will review whether use of BCG is optimal for all non-muscle invasive bladder cancers. There is a gap in the understanding of whether every patient needs a cystectomy. This will be reviewed and defined.

Many urologists may not practice pediatric urology but must be able to deal with basic pediatric urologic issues in the emergency department and their clinic. We will cover key pediatric urology emergencies. We will also discuss how congenital anomalies into adulthood affect the urologic care by an adult urologist.
Educational Objectives
At the conclusion of the 40th Annual Winter Urologic Forum, attendees should be able to:

1. Explain management of common pediatric urologic emergencies.
2. Identify treatment options for female and male incontinence.
3. Describe detailed treatment options that are appropriate for patients with bladder and prostate cancer.
4. Explain the appropriate evaluation and management of the overlapping conditions of urinary tract infections and painful urologic symptoms.
5. Identify the current status of legal issues surrounding the treatment using prosthetics.
6. Recognize the benefits and drawbacks of prostate cancer genomic testing and MRI.
7. Evaluate up-to-date data surrounding urolithiasis imaging and treatment.
8. Assess the use of BCG in bladder cancer.
9. Review the use of combined treatment for LUTS and ED.
10. Describe data regarding use of adjuvant versus salvage radiotherapy for post-prostatectomy patients.
Nurses and other healthcare professionals will receive a Certificate of Attendance. For information on the applicability and acceptance of Certificates of Attendance for educational activities certified for **AMA PRA Category 1 Credit™** from organizations accredited by the ACCME, please consult your professional licensing board.

**General Disclaimer**

The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Winter Urologic Forum. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Winter Urologic Forum disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

**Special Assistance**

We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517-7225, if you require special assistance to fully participate in the meeting.
Thank You to Our 2016 Promotional Partners
(alphabetical as of 1/4/2016)

Platinum Level
Janssen Biotech, Inc.

Gold Level
Medivation
sanofi Oncology

Thank you to Our 2016 Contributors
(alphabetical as of 1/4/2016)

Genomic Health
Janssen Biotech, Inc.
MDxHealth
sanofi Oncology
Thank You to Our 2016 Exhibitors
(alphabetical as of 1/4/2016)

AbbVie
GenomeDx Biosciences, Inc.
Genomic Health
Hitachi-Aloka Medical
Janssen Biotech, Inc.
Medivation
Photocure
sanofi Oncology
TOLMAR Pharmaceuticals
### SATURDAY, JANUARY 16, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Speaker: Christopher Evans, MD, FACS</td>
<td></td>
<td>Professor and Chair, Department of Urology</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>University of California, Davis School of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacramento, California</td>
</tr>
</tbody>
</table>

### SATURDAY, JANUARY 16, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m. – 6:45 p.m.</td>
<td>Industry Satellite Symposium</td>
<td>Grand Ballroom Salon G, Conference Level</td>
<td>“An Epigenetic Assay to Improve Patient Stratification on the Decision for Repeat Biopsy”</td>
</tr>
<tr>
<td></td>
<td>Speaker: Christopher Evans, MD, FACS</td>
<td></td>
<td>Professor and Chair, Department of Urology</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>University of California, Davis School of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacramento, California</td>
</tr>
</tbody>
</table>

### SUNDAY, JANUARY 17, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:15 a.m. – 7:15 a.m.</td>
<td>Industry Satellite Symposium Breakfast</td>
<td>Grand Ballroom Salon G, Conference Level</td>
<td>“Key Clinical Findings For Patients With mCRPC That Has Progressed On Androgen Deprivation Therapy”</td>
</tr>
<tr>
<td></td>
<td>Speaker: Christopher P. Evans, MD, FACS</td>
<td></td>
<td>Professor and Chair, Department of Urology</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>University of California, Davis School of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sacramento, California</td>
</tr>
</tbody>
</table>

### MONDAY, JANUARY 18, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:15 a.m. – 7:15 a.m.</td>
<td>Industry Satellite Symposium Breakfast</td>
<td>Grand Ballroom Salon G, Conference Level</td>
<td>“Integrating Oncotype DX® GPS into Clinical Practice”</td>
</tr>
<tr>
<td></td>
<td>Speaker: Steven Canfield, MD</td>
<td></td>
<td>University of Texas Medical School at Houston</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Houston, Texas</td>
</tr>
</tbody>
</table>
40th Annual Winter Urologic Forum
January 15 - 19, 2016
Vail Marriott Mountain Resort

Plenary sessions will take place in the Grand Ballroom Salon A-E, Conference Level, unless otherwise noted. Speakers and times are subject to change.

FRIDAY, JANUARY 15, 2016

OVERVIEW
5:00 p.m. - 7:00 p.m.  Registration/Information Desk Open
Location: Grand Ballroom Registration Desk, Conference Level

SATURDAY, JANUARY 16, 2016

OVERVIEW
6:00 a.m. - 9:00 a.m.  Registration/Information Desk Open
Location: Grand Ballroom Registration Desk, Conference Level

6:15 a.m. - 7:15 a.m.  Industry Sponsored Breakfast Symposium
Location: Grand Ballroom Salon G, Conference Level

7:00 a.m. - 9:30 a.m.  Exhibit Hall Open
Location: Grand Ballroom Salon F, Conference Level

3:30 p.m. - 6:30 p.m.  Registration/Information Desk Open
Location: Grand Ballroom Registration Desk, Conference Level

3:30 p.m. - 7:45 p.m.  Exhibit Hall Open
Location: Grand Ballroom Salon F, Conference Level

GENERAL SESSION

7:15 a.m. - 9:15 a.m.  SESSION I: Lower Urinary Tract Symptoms and ED
Moderator: Roger R. Dmochowski, MD, MMHC, FACS

7:15 a.m. - 7:45 a.m.  BPH and ED: Medical Management - Does Dual Therapy Make Sense?
Speaker: Douglas F. Milam, MD

7:45 a.m. - 8:15 a.m.  ED: From Needles to Prosthetics and Post-RP Rehab
Speaker: Douglas F. Milam, MD

8:15 a.m. - 8:35 a.m.  Complications and Management of Penile Prosthetics
Speaker: Douglas F. Milam, MD

8:35 a.m. - 9:15 a.m.  Prosthetic Complications: Legal Issues and Considerations
Panelists: Roger R. Dmochowski, MD, MMHC, FACS
Douglas F. Milam, MD
Jennifer G. Rothschild, MD, MPH
Ben B. Rubinowitz, JD
Matthew P. Rutman, MD

9:15 a.m. - 9:30 a.m.  Break - Visit with Exhibitors

9:30 a.m. - 3:30 a.m.  Video Session
4:00 p.m. - 6:00 p.m. SESSION II: Bladder Cancer
Moderator: James M. McKiernan, MD

4:00 p.m. - 4:30 p.m. Optimizing Outcomes in Bladder Cancer: Implementing the Guidelines
Speaker: James M. McKiernan, MD

4:30 p.m. - 5:00 p.m. Is BCG Taking Over the Treatment of NMIBC?
Speaker: Christopher P. Evans, MD, FACS

5:00 p.m. - 5:30 p.m. Does Every Patient with Muscle Invasive Bladder Cancer Need Cystectomy?
Speaker: Mitchell C. Benson, MD

5:30 p.m. - 6:00 p.m. Case Presentations in the Decisions and Nuances of Urothelial Cancer
Moderator: Marc A. Dall’Era, MD
Panelists: Daniel A. Barocas, MD, MPH, FACS
Christopher P. Evans, MD, FACS
James M. McKiernan, MD
Alan M. Nieder, MD

6:00 p.m. - 6:45 p.m. Industry Sponsored Symposium
Location: Grand Ballroom Salon G, Conference Level

6:45 p.m. - 7:45 p.m. Welcome Reception
Location: Grand Ballroom Salon F, Conference Level

SUNDAY, JANUARY 17, 2016

OVERVIEW

6:15 a.m. - 7:15 a.m. Industry Sponsored Breakfast Symposium
Location: Grand Ballroom Salon G, Conference Level

6:30 a.m. - 9:00 a.m. Registration/Information Desk Open
Location: Grand Ballroom Registration Desk, Conference Level

7:00 a.m. - 9:30 a.m. Exhibit Hall Open
Location: Grand Ballroom Salon F, Conference Level

3:30 p.m. - 6:30 p.m. Registration/Information Desk Open
Location: Grand Ballroom Registration Desk, Conference Level

3:30 p.m. - 6:00 p.m. Exhibit Hall Open
Location: Grand Ballroom Salon F, Conference Level

GENERAL SESSION

7:15 a.m. - 9:15 a.m. SESSION III: The Changing Face of Prostate Cancer
Moderator: Mitchell C. Benson, MD

7:15 a.m. - 7:40 a.m. Biomarkers Beyond PSA
Speaker: Christopher P. Evans, MD, FACS

7:40 a.m. - 8:05 a.m. Genomics vs. MRI
Speaker: Marc A. Dall’Era, MD

8:05 a.m. - 8:30 a.m. Adjuvant vs. Salvage XRT: How I Select Those Who Might Benefit
Speaker: Mitchell C. Benson, MD

8:30 a.m. - 9:15 a.m. Cases and Controversies in Prostate Cancer
Moderator: James M. McKiernan, MD
Panelists: Daniel A. Barocas, MD, MPH, FACS
Mitchell C. Benson, MD
Marc A. Dall’Era, MD
Christopher P. Evans, MD, FACS
Alan M. Nieder, MD

9:15 a.m. - 9:30 a.m. Break - Visit with Exhibitors

9:30 a.m. - 3:30 p.m. Video Session

3:30 p.m. - 4:00 p.m. Apres Ski in the Exhibit Hall
Location: Grand Ballroom Salon F, Conference Level
4:00 p.m. - 5:30 p.m.  SESSION IV: Endourology and Office Urology
Moderator: Marc A. Dall’Era, MD

4:00 p.m. - 4:30 p.m.  Imaging of Urinary Stone Disease
Speaker: Roger K. Low, MD

4:30 p.m. - 5:00 p.m.  Recurrent UTI’s in Females
Speaker: Kimberly L. Cooper, MD

5:00 p.m. - 5:30 p.m.  What is New in the Surgical Management of Stone Disease
Speaker: Ojas Shah, MD

5:30 p.m. - 6:00 p.m.  SESSION V: Cytoreductive Radical Prostatectomy for Oligometastic Prostate Cancer
Speaker: Daniel A. Barocas, MD, MPH, FACS

MONDAY, JANUARY 18, 2016

OVERVIEW

6:15 a.m. - 7:15 a.m.  Industry Sponsored Breakfast Symposium
Location: Grand Ballroom Salon G, Conference Level

6:30 a.m. - 9:00 a.m.  Registration/Information Desk Open
Location: Grand Ballroom Registration Desk, Conference Level

7:00 a.m. - 10:30 a.m.  Exhibit Hall Open
Location: Grand Ballroom Salon F, Conference Level

3:30 p.m. - 6:30 p.m.  Registration/Information Desk Open
Location: Grand Ballroom Registration Desk, Conference Level

3:30 p.m. - 6:00 p.m.  Exhibit Hall Open
Location: Grand Ballroom Salon F, Conference Level

GENERAL SESSION

7:15 a.m. - 9:15 a.m.  SESSION VI: Female Incontinence/Women’s Health
Moderator: Christopher P. Evans, MD, FACS

7:15 a.m. - 7:45 a.m.  Conservative and Medical Management of OAB
Speaker: Jennifer G. Rothschild, MD, MPH

7:45 a.m. - 8:05 a.m.  Conservative Management of SUI
Speaker: Roger R. Dmochowski, MD, MMHC, FACS

8:05 a.m. - 8:35 a.m.  Management Options for Medicine Refractory OAB
Speaker: Jennifer G. Rothschild, MD, MPH

8:35 a.m. - 8:55 a.m.  Surgical Interventions for SUI
Speaker: Roger R. Dmochowski, MD, MMHC, FACS

8:55 a.m. - 9:15 a.m.  Cases in Female Urology
Moderator: Roger R. Dmochowski, MD, MMHC, FACS
Panelists: Kimberly L. Cooper, MD
Jennifer G. Rothschild, MD, MPH
Matthew P. Rutman, MD

9:45 a.m. - 10:15 a.m.  Break - Visit with Exhibitors

10:15 a.m. - 3:30 p.m.  Video Session

3:30 p.m. - 4:00 p.m.  Apres Ski in the Exhibit Hall
Location: Grand Ballroom Salon F, Conference Level

4:00 p.m. - 4:30 p.m.  SESSION VII: “Valued-Based Care” - What is It and How Will It Affect Your Practice?
Speaker: Daniel A. Barocas, MD, MPH, FACS

4:30 p.m. - 6:00 p.m.  SESSION VIII: Medical Malpractice
Moderator: Mitchell C. Benson, MD

Medico- Legal Pitfalls of the Electronic Medical Record
Speaker: Ben B. Rubinowitz, JD
TUESDAY, JANUARY 19, 2016

OVERVIEW

6:30 a.m. - 9:00 a.m.  Registration/Information Desk Open
Location: Colorado Ballroom Foyer, 2nd Level

6:30 a.m. - 7:15 a.m.  Breakfast
Location: Colorado Ballroom Foyer, 2nd Level

GENERAL SESSION

7:15 a.m. - 9:15 a.m.  SESSION IX: Endourology and Pediatric Urology for the General Urologist
Moderator:  Roger K. Low, MD
Location: Colorado Ballroom, 2nd Level

7:15 a.m. - 7:45 a.m.  Pediatric Urology Emergency Department Consultations
Speaker:  Eric A. Kurzrock, MD, FAAP
Location: Colorado Ballroom, 2nd Level

7:45 a.m. - 8:30 a.m.  Medical Evaluation and Management of Stone Disease
Speaker:  Roger K. Low, MD
Location: Colorado Ballroom, 2nd Level

8:30 a.m. - 9:15 a.m.  Transitional Care - Adults with Congenital Anomalies
Speakers:  Eric A. Kurzrock, MD, FAAP
           Jennifer G. Rothschild, MD, MPH
Location: Colorado Ballroom, 2nd Level

9:15 a.m.  Meeting Adjourns

Disclaimer Statement
Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of the WUF nor does the WUF provide any warranty as to their accuracy or reliability.

Every effort has been made to faithfully reproduce the abstracts as submitted. However, no responsibility is assumed by the WUF for any injury and/or damage to persons or property from any cause including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.
Daniel A. Barocas, MD, MPH, FACS

Daniel A. Barocas, MD, MPH, FACS is a urologic oncologist and health services researcher on staff at the Vanderbilt University Medical Center, and the Vanderbilt Ingraham Cancer Center. He received his medical degree at the Johns Hopkins University School of Medicine and went on to complete a residency in urology at the New York Presbyterian Hospital-Weill Cornell Medical Center. He then came to Vanderbilt University Medical Center, where he completed a two-year fellowship in urologic oncology and a master of public health degree. He has remained at Vanderbilt on faculty since completing his fellowship.

Dr. Barocas’ clinical interest is the surgery and management of genitourinary cancers. He is experienced in open and laparoscopic surgery and is a leader in robotic surgery for genitourinary cancers. Dr. Barocas is a strong patient advocate who partners with patients and families to treat the cancer while preserving quality of life. His research interests include: 1) identifying and ameliorating inappropriate variation in the quality care for genitourinary cancers, such as race- and gender-based variation; 2) quality improvement and patient safety; 3) comparative effectiveness of treatments for urologic cancers. Dr. Barocas’ research efforts have been funded by Federal agencies, including National Cancer Institute, the Agency for Healthcare Research and Quality, and the Patient-Centered Outcomes Research Institute. He has authored more than 100 peer-reviewed articles in journals including Journal of Urology, Journal of the American College of Surgeons, and Cancer.

Dr. Barocas is the co-director of the Center for Surgical Quality and Outcomes Research at Vanderbilt, and is the co-Principal Investigator of the Comparative Effectiveness Assessment of Surgery and Radiation (CEASAR) study, which seeks to compare different treatment strategies for localized prostate cancer. Dr. Barocas serves in a number of leadership positions in academic urology, including being a member of the 2015 American Urological Association (AUA) Leadership Program. He currently serves on the AUA’s Quality Improvement and Patient Safety Committee, represents AUA as liaison to the Commission on Cancer, and serves as an assistant editor for Prostate Cancer for the Journal of Urology. He has served as committee member on guideline panels for the American Urological Association and the National Comprehensive Cancer Network. He also serves on the Quality Integration Committee for the Commission on Cancer, where guidelines for cancer care are developed and implemented. Dr. Barocas is the current president of the Young Urologic Oncology, a subgroup of the Society of Urologic Oncology.

Mitchell C. Benson, MD

Mitchell Benson, MD began his affiliation with Columbia University College of Physicians and Surgeons in the autumn of 1973 when he enrolled in Columbia P&S as a first year medical student. He recognized early in his training that he wished to pursue a career in urology and, following an internship and residency in general surgery at Mount Sinai Hospital in New York, he became a resident in urology at The Presbyterian Hospital in New York in 1979. Following his chief residency in urology at The Presbyterian Hospital, he went to Johns Hopkins Hospital and University where he was a research fellow in urologic oncology from 1982 – 1984.

After completion of his fellowship, Dr. Benson returned to Columbia University P&S to join the urology faculty. Dr. Benson was one of the first recipients of the Herbert Irving Assistant Professor awards and he was the Herbert Irving Assistant Professor of Urology from July 1988 – June 1991. He was then promoted to associate professor of urology, and in July 1995 to professor of urology. In 1997, he was named the George F. Cahill Professor of Urology. In November 2003, he was named the director of the Comprehensive Cancer Center of Columbia University. He was appointed The George F. Cahill Professor and chairman of the department of urology and urologist-in-chief at Columbia University Medical Center in 2005.

During his career, Dr. Benson has been the recipient of numerous honors. After having been elected to Phi Beta Kappa at Union College, he was awarded the urology prize from Columbia University College of P&S. During his residency, he was awarded first prize at the New York Academy of Medicine in the Ferdinand C. Valentine Residents’ Essay Contest. He has won prizes for his clinical research from the American Urological Association in 1987 and 1991.

Dr. Benson’s research has been and continues to be supported by the National Cancer Institute, and he has participated in numerous projects sponsored by the pharmaceutical industry. He has submitted or published over 175 scientific articles since 1984 and has presented more than 200 papers at National Meetings.
Kimberly L. Cooper, MD

Kimberly L. Cooper, MD received her undergraduate degree from Harvard University and her medical degree from the Columbia University College of Physicians and Surgeons. She completed her urology residency training at New York-Presbyterian Hospital/Columbia University Medical Center before completing a fellowship in voiding dysfunction, female urology and neurourology at the same institution.

Dr. Cooper’s clinical and research interests are in male and female incontinence, vaginal prolapse, voiding dysfunction, urodynamics and surgical outcomes. Additionally, she is interested in managing the various urologic disorders that affect women.

She is the Residency Program Director for the Urology Program at Columbia and is actively involved in the education of medical students.

Dr. Cooper’s professional associations are: American Urological Association; American Urological Association, New York section; American Association of Clinical Urologists; Society of Women in Urology; and Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction.

Marc A. Dall’Era, MD

Marc Dall’Era, MD received his BS in microbiology and MD from the University of California, Davis to return in 2008 as an assistant professor of clinical urology. In July 2013, Dr. Dall’Era became an assistant professor and vice-chairman of the department of urology at the University. After earning his degrees, Dr. Dall’Era performed his residency in urology at the University of Washington in Seattle, Washington, where he was chief resident from 2005 – 2006. After the completion of his residency, Dr. Dall’Era completed a fellowship in oncology at University of California, San Francisco.

Dr. Dall’Era’s residency and fellowship training prepared him for clinical duties and basic science research in the comprehensive and multidisciplinary approach to evaluating and treating genitourinary cancers. His surgical experience includes both open and laparoscopic procedures, including laparoscopic prostatectomy with the da Vinci robotic system.

Dr. Dall’Era’s oncology fellowship was primarily devoted to basic and translational research. He worked in the lab of Dr. Robert Blellach focusing on isolating and characterizing prostatic tumor stem cells. His clinical research focus was on active surveillance and clinical outcomes for men with prostate cancer. A member of the American Urological Association, the American Association of Clinical Urologists and the Western Section of the AUA, Dr. Dall’Era’s work has appeared in numerous journals and several book chapters.
Roger R. Dmochowski, MD, MMHC, FACS
Roger Dmochowski, MD, MMHC is a professor in the departments of urology and obstetrics and gynecology at Vanderbilt University in Nashville, Tennessee. Dr. Dmochowski is also a clinical assistant professor of surgery at the Uniformed Services University of the Health Sciences in Bethesda, Maryland; director of the Female Pelvic Medicine and Reconstructive Surgery Fellowship program at Vanderbilt University; and executive physician for safety at Vanderbilt University Hospital. He also serves as vice chair of the Section of Surgical Sciences (quality, safety, and professionalism), associate chief of staff and medical director for risk management at Vanderbilt University Medical Center.

Dr. Dmochowski earned his medical degree from the University of Texas Medical Branch at Galveston. He completed an internship and residency in surgery and urology at the University of Texas Medical School at Houston and at the University of Texas MD Anderson Hospital and Tumor Institute in Houston. In addition, Dr. Dmochowski is subspecialty-fellowship trained in female urology, neurourology, urodynamics and reconstructive urology, as well as board certified in urology.

Dr. Dmochowski has taken a leadership position in the development and subsequent certification of the new specialty of female pelvic medicine and reconstruction. The process was carried out in concert with the American Urological Association and the American Board of Urology. During this time frame (ten years), he served as a member of the American Board of Urology/American Board of Obstetrics and Gynecology Oversight Committee, which developed the requirements and infrastructure for these fellowships. He was also responsible for direct communication with both the Society for Urodynamics, Female Pelvic Medicine, and Urogynecology, and Urogynecology and Urogynecology, as well as general membership in the American Urological Association in regard to this process. As a member of the Oversight Committee, he contributed to the development of the written examination, which will be used for subspecialty certification, and oversight of programs within this subspecialty. He also served on a special subcommittee as the only urologist interfacing with the Accreditation Council for Graduate Medical Education for purposes of developing ACGME-approved criteria for these programs.

Dr. Dmochowski has published over 300 articles and book chapters, 320 abstracts and has given over 180 presentations at various national and international meetings. He has been featured in videotapes and CD-ROMs on the management of urinary incontinence. Dr. Dmochowski is on the editorial board for the World Journal of Urology, Neuromodulation and Nurology and International Journal of Urogynecology. He is a reviewer for the Journal of Urology and Urology.

Christopher P. Evans, MD, FACS
Christopher Evans, MD, FACS is currently a professor and chairman in the department of urology at the University of California, Davis School of Medicine in Sacramento. Dr. Evans attended the Geisel School of Medicine at Dartmouth College and performed surgery and urology training at the University of California, San Francisco, where he was also a National Kidney Foundation Scholar. He then completed his surgical urologic oncology training at the University of Texas, MD Anderson Cancer Center.

He is a member of the UC Davis Comprehensive Cancer Center, co-leader of the Prostate Cancer Program and chairman of the UC Davis Medical Group Practice Management Board. Dr. Evans studies oncogenic activation of the androgen receptor and mechanisms regulating castration-resistant prostate cancer. His basic science work has translated into clinical trial and he has received funding from the NIH, DOD, Prostate Cancer Foundation, Stand-Up to Cancer and New York Academy of Medicine.

He is a president-elect and executive committee member of the Society of Urologic Oncology and immediate past chair of the Steering Committee of ASCO GU. Dr. Evans has also published over 130 peer-reviewed articles.
Eric A. Kurzrock, MD, FAAP
Eric A. Kurzrock, MD, FAAP is professor of urology at the University of California, Davis School of Medicine in Sacramento. He is the chief of pediatric urologic surgery at the UC Davis Children's Hospital and Shriners Hospital for Children – Northern California. Dr. Kurzrock graduated from UC Berkeley in biochemistry then went on to UCLA School of Medicine. He completed general surgery and urology training at USC and then a pediatric fellowship at UCSF.

Dr. Kurzrock is the director of the urologic stem cell laboratory in the UC Davis Institute for Regenerative Cures. He has received funding from Shriners Hospital, CIRM and NIH. His laboratory was the first to identify and characterize adult urothelial stem cells and also the first to induce human embryonic stem cells and iPS cells into urothelium. He also investigates bladder bioengineering and is currently funded to evaluate angiogenesis in tissue engineering models. Dr. Kurzrock has also written extensively on pediatric urologic outcomes.

Dr. Kurzrock currently chairs Clinical Quality Improvement for the department and serves on the Quality Safety Operations Committee, Children’s Surgery Performance Improvement and Patient Safety Committee, Electronic Medical Record Faculty Committee and the Practice Management Board Finance Committee. He is a past member of the Society of Pediatric Urology executive committee and is currently a member of the Journal of Urology editorial committee.

Roger Low, MD
Roger Low, MD is a professor of urology at the University of California, Davis. He has held an academic practice in the area of endourology/stone disease for 20-plus years. His clinical practice focuses on providing comprehensive care to patients with complex urinary stone disease.
James M. McKiernan, MD  
James McKiernan, MD graduated from Johns Hopkins University in 1989 with a BA in biology and received his medical degree from Columbia University College of Physicians and Surgeons in 1993. He has remained affiliated with New York-Presbyterian/Columbia University Medical Center for the past 22 years, completing his training in urology and general surgery at the medical center in 1999. Dr. McKiernan then completed a two-year urologic surgical oncology fellowship studying at Memorial Sloan-Kettering Cancer Center. In 2001, Dr. McKiernan was appointed as an assistant professor of urology at Columbia University College of Physicians and Surgeons. Dr. McKiernan was named the John and Irene Given Endowed Chair in Urology and in 2007 was named associate professor of clinical urology. In 2010, Dr. McKiernan was promoted to a professor of clinical urology and has served as the vice chairman of urology and director of urologic oncology since 2006.

Dr. McKiernan's practice is limited exclusively to urologic oncology, including surgical therapy of bladder, kidney, prostate and testicular cancer. He has a specific interest in treating patients diagnosed with recurrent or high risk cancer diagnoses. In the management of kidney and bladder cancer, Dr. McKiernan has developed specific expertise in organ preservation and reconstructive surgery to maximize quality of life.

Dr. McKiernan is actively involved in research and discovery with ongoing programs focused on improving patient clinical outcomes with kidney, prostate and bladder cancer and has been published in Urology, Journal of Urology, Journal of Clinical Oncology and Urologic Oncology among others. He has authored and co-authored more than 130 scientific articles and book chapters in the field of urologic oncology. For the past ten years, he has directed the research efforts at Columbia University in quality outcomes and effectiveness research in urologic cancer surgery. In addition, Dr. McKiernan directs the experimental clinical trials program in intravesical therapy for bladder cancer. This program has helped develop promising new agents for bladder preservation in patients whose cancer has recurred after the use of BCG therapy. In collaboration with the research scientists in the Herbert Irving Comprehensive Cancer Center, this team continues to develop new therapeutic strategies for managing bladder cancer.

Dr. McKiernan is currently the director of urologic medical student education in the Columbia University College of Physicians and Surgeons and is the John and Irene Given Professor of Urology at Columbia University. He is the director of the third and fourth year medical student course in urology and lectures annually to the first and second year medical student class. Since 2002, he has served as the mentor and director of the medical student Doris Duke Charitable Foundation Clinical Scholars Research Fellowship in Urology. Through this position, Dr. McKiernan has had the honor of mentoring 16 research fellows over the past ten years who have gone on to become future leaders in the field of urology. He is also the dean's advisor for career counseling in urology for students in the College of Physicians and Surgeons and serves on the curriculum development committee for the college. In 2004, Dr. McKiernan was voted “teacher of the year” by the residents of the urology department.

Douglas F. Milam, MD  
Douglas Milam, MD is an associate professor in the department of urologic surgery at Vanderbilt University School of Medicine. He received a BSE degree in bioengineering from the University of Pennsylvania in 1980, Dr. Milam earned his MD from West Virginia University. He then completed a residency in urology at the University of Utah in 1991. The focus of his clinical practice is men's health. In particular, male incontinence, erectile dysfunction, Peyronie's disease and urethral stricture disease represent most of his patient treatment effort.

Since 1991, he has been an attending physician at Vanderbilt University Hospital. He also has appointments at Saint Thomas Midtown Hospital, Metropolitan Nashville General Hospital, and the Cool Springs Surgical Center. Dr. Milam also serves on the Vanderbilt Laser Committee, Vanderbilt Perioperative Redesign Committee, Cool Springs Surgical Center Board.

Dr. Milam is member of the American Urological Association, Sexual Medicine Society of North America, Society of Urologic Prosthetic Surgeons, and is a Fellow American College of Surgeons. He continues to be involved in research and publish in peer-reviewed journals.
Alan M. Nieder, MD
Alan M. Nieder, MD is an associate professor of urology at Columbia University's Division of Urology at Mount Sinai Medical Center in Miami Beach, Florida. Dr. Nieder is the program director of the newly ACGME-accredited Urology Residency at Mount Sinai Medical Center. He oversees and coordinates all aspects of the education and training of the residents, fellows and rotating medical students.

Dr. Nieder's undergraduate degree is from the University of Michigan, Ann Arbor, and he received his medical degree from New York University School of Medicine. Dr. Nieder also completed his urology residency training at New York University Medical Center. He subsequently undertook a fellowship in urologic oncology at the University of Miami/Jackson Memorial Hospital.

Dr. Nieder's clinical interests include urologic oncology, laparoscopy and endourology. He has authored numerous publications on bladder and prostate cancer. His research interests are in bladder cancer and specifically in improving outcomes of patients with both non-muscle invasive and invasive bladder cancer. He has authored and co-authored more than 50 articles, book chapters and abstracts in the field of urology and urologic oncology. His research has been published in Journal of Urology, Urology, European Urology, Urologic Oncology, among others. He is also an active reviewer and editor of many national and international urologic journals. He is an active member of many urologic societies and is a member on the board of the Florida Urologic Society as well.

Jennifer G. Rothschild, MD, MPH
Jennifer Rothschild, MD, MPH attended Boston University School of Public Health with a focus on health law where she earned her MA/MPH. She then completed medical school at the Boston University School of Medicine. She fulfilled her urology residency in upstate New York at the University of Rochester. Dr. Rothschild completed her fellowship in female pelvic medicine and reconstructive surgery at Vanderbilt University. She currently is an assistant professor faculty with the department of urology at UC Davis Medical System in Sacramento, California.

Dr. Rothschild specializes in the diagnosis and treatment of male and female urinary incontinence. Her expertise includes neuro-urology, lower urinary tract reconstruction, and prosthetic surgery.

Currently Dr. Rothschild research includes outcomes of the revised artificial urinary sphincter, radiation impact on urethral reconstruction, and BMI influence on female stress incontinence.
Ben B. Rubinowitz, JD
Throughout his 30-year legal career, Ben Rubinowitz has made his mark as a leading trial lawyer combining hard work and dedication with his remarkable courtroom skills and presence. Mr. Rubinowitz began his career as a prosecutor, where he honed the trial skills that would become his hallmark. From there, he began serving as a trial lawyer representing severely injured plaintiffs in personal injury cases, eventually joining GGC&R&BHS&M in 1989. For the past 12 years Mr. Rubinowitz was featured in New York Magazine’s article on “Best Lawyers in New York” and was recently named “Best Lawyers, Lawyer of the Year.” Ben is one of the few lawyers in the country to be recognized twice as “Lawyer of the Year.” He is one of ten GGC&R&BHS&M attorneys who were listed in “The Best Lawyers in America”- which is more than any other New York plaintiff’s personal injury firm. For the past nine years, Ben has been recognized in the New York Times as one of the “Top 100” lawyers in the New York Metro area, as evaluated by New York Super Lawyers. Ben was honored by being elected to be a member of the prestigious Inner Circle of Advocates. The Inner Circle of Advocates is limited to 100 members considered among the best plaintiffs’ attorneys in the United States and also to be "lawyers of excellent character and integrity."

Ben's meticulous approach to the preparation and trial of cases has produced 21 verdicts and over 100 settlements in excess of one million dollars in cases arising out of car accidents, premises accidents, construction accidents, medical malpractice, civil rights violations and products liability. Mr. Rubinowitz has a thorough grasp of the nuances of complex issues. This, coupled with his ability to translate complicated information into clear terms for a jury, has left an indelible impression on all those who have witnessed him in action--including even defendants' medical experts that he has cross-examined. In addition to his skills as a trial lawyer, Mr. Rubinowitz has successfully argued appellate cases before the Appellate Division and the highest court in the State of New York, the Court of Appeals.

Mr. Rubinowitz's experience and legal acumen is also sought out outside of the courtroom. He has appeared as a legal expert on Court TV and co-authors a regular column in the NY Law Journal on the subject of trial advocacy. His successes as a trial lawyer and expertise in his field have earned him national recognition as a trial advocacy teacher both to attorneys and to law students. Mr. Rubinowitz has lectured, chaired, and participated in seminars and programs at Harvard, Yale, Emory, Fordham, Hofstra, St. John's, Pace and Cardozo law schools, as well as more than 100 continuing legal education programs throughout the country and internationally. In recognition of his trial skills, Mr. Rubinowitz has been asked by the National Institute for Trial Advocacy to serve as a national and regional team leader and thereafter, ultimately elected to the prestigious position of a National Board Member of the National Institute for Trial Advocacy. And, more recently, Mr. Rubinowitz was asked by the Duke University School of Medicine and Columbia University, College of Physicians and Surgeons to lecture physicians about Medical Malpractice at the National Urologic Forum.

Matthew P. Rutman, MD
Matthew P. Rutman, MD is the co-director of Voiding Dysfunction, Incontinence and Urodynamic Center at New York Presbyterian Hospital/Columbia University Medical Center. He is an assistant professor of clinical urology at Columbia University College of Physicians and Surgeons. He graduated with honors from Emory University and The Chicago Medical School. After completing his residency at William Beaumont Hospital, Dr. Rutman completed a fellowship in female urology, voiding dysfunction, neurourology and urodynamics under world renowned Shlomo Raz, MD at the UCLA Medical Center. Dr. Rutman is also a co-director of urology at Allen Fellowship, as well as a director with the Voiding Dysfunction and Endourology Fellowship.
Ojas Shah, MD

Ojas Shah, MD is a professor of urology and director of endourology and stone disease at Columbia University Medical Center/NewYork Presbyterian Hospital. His clinical interests include surgical and metabolic treatments of kidney stone disease, minimally invasive urologic surgery, upper tract transitional cell carcinoma/urothelial carcinoma, ureteral strictures, ureteropelvic junction (UPJ) obstruction, ureteral/renal reconstructive surgery, and BPH (benign prostate hyperplasia).

Dr. Shah is a graduate of Northwestern University School of Medicine. He completed his general surgical and urologic training at New York University Medical Center. He spent an additional year at Wake Forest University Health Sciences Center as a fellow in endourology, laparoscopy and metabolic stone disease.

Dr. Shah is nationally active as a member of the American Urological Association Surgical Management of Stones Guidelines Committee. He holds the honor of being inducted into the ROCK (Research on Calculous Kinetics) Society, a research society of basic scientists, nephrologists and urologists with a primary interest in kidney stone disease. Recently, Dr. Shah was named the assistant editor to the *Journal of Urology*, among the most highly cited and respected international journals in the field. He also has a strong focus on medical student and resident education, and served as the urology residency program director at NYU School of Medicine prior to joining Columbia University.